HAEMOSTATIC POLYMER-BASED AGENT CONTAINING MICROPARTICLES AND IRON OXIDE NANOPARTICLES, AND METHODS FOR PREPARING PHARMACOLOGICAL FORMS THEREOF Russian patent published in 2020 - IPC A61K33/26 A61K47/36 A61K47/38 A61K47/58 A61P7/04 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, specifically to a haemostatic polymer-based agent containing a polymer and active components, characterized in that it contains a natural or synthetic polymer in amounts sufficient for gel-based production thereof, and as active components there is a mixture of powders of iron oxides in the form of three main crystalline modifications: hematite microparticles (α-Fe₂O₃) and magnetite (Fe₃O₄), as well as epsilon-phase (ε-Fe₂O₃), presented in the form of nanoparticles, up to 0.8 wt. %, where the natural haemostatic agent contains sodium alginate, chitosan, kappa-carrageenan, a biopolymer material of bacterial cellulose, and the synthetic polymer is polyvinylpyrrolidone, also relates to a method for preparing a haemostatic agent based on natural or synthetic polymers in the form of a gel, characterized in that the natural polymer or synthetic polymer is dissolved in distilled water at temperature from +20 to +75 °C in an amount sufficient to obtain 0.1–50.0 wt. % solution, then added to 0.8 wt. % of iron oxide powder in the form of three main crystalline modifications: hematite microparticles (α-Fe₂O₃) and magnetite (Fe₃O₄), as well as epsilon-phase (ε-Fe₂O₃), presented in the form of nanoparticles, and is brought into the shaker at constant stirring for 30 minutes until formation of a homogeneous gel, wherein ratio of components in 1 litre of final gel: natural or synthetic polymer - 0.1–50.0 wt. %, mixture of powders of iron oxide in form of three main crystalline modifications: hematite microparticles (α-Fe₂O₃) and magnetite (Fe₃O₄), as well as epsilon-phase (ε-Fe₂O₃), presented in form of nanoparticles, up to 0.8 wt. %, water - balance, where as natural polymers haemostatic agent contains sodium alginate, chitosan, kappa-carrageenan, a biopolymer material of bacterial cellulose, and the synthetic polymer contains polyvinylpyrrolidone.

EFFECT: group of inventions widens the range of haemostatic agents with pronounced haemostatic action and excluding direct adverse effect (occlusion of blood vessels and ischemia of nearby healthy tissues) active substance on wound surface and surrounding tissues.

7 cl, 40 ex, 20 tbl